1.75
Iovance Biotherapeutics Inc stock is traded at $1.75, with a volume of 111.99M.
It is down -44.79% in the last 24 hours and down -46.48% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$3.17
Open:
$1.94
24h Volume:
111.99M
Relative Volume:
9.94
Market Cap:
$1.17B
Revenue:
$32.77M
Net Income/Loss:
$-440.22M
P/E Ratio:
-1.0479
EPS:
-1.67
Net Cash Flow:
$-400.48M
1W Performance:
-50.00%
1M Performance:
-46.48%
6M Performance:
-83.47%
1Y Performance:
-86.99%
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IOVA
Iovance Biotherapeutics Inc
|
1.75 | 1.17B | 32.77M | -440.22M | -400.48M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
Oct-24-24 | Initiated | UBS | Buy |
Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Nov-20-23 | Initiated | Goldman | Buy |
Sep-18-23 | Reiterated | Barclays | Overweight |
May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
Oct-31-22 | Initiated | Guggenheim | Neutral |
Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
Jan-28-22 | Upgrade | Stifel | Hold → Buy |
Dec-07-21 | Resumed | Cowen | Outperform |
Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
May-19-21 | Downgrade | Stifel | Buy → Hold |
May-03-21 | Initiated | Truist | Buy |
Apr-16-21 | Initiated | Goldman | Buy |
Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-22-20 | Initiated | Mizuho | Buy |
Mar-04-20 | Initiated | Barclays | Overweight |
Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
Feb-26-20 | Reiterated | Oppenheimer | Outperform |
Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
Oct-01-19 | Initiated | Stifel | Buy |
Apr-29-19 | Initiated | Piper Jaffray | Overweight |
Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
Feb-07-19 | Initiated | Robert W. Baird | Outperform |
Dec-31-18 | Resumed | B. Riley FBR | Buy |
Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Market Today: Trade Desk Surges on Strong Earnings; Iovance Biotherapeutics Plummets - GuruFocus
Iovance Biotherapeutics (IOVA) Downgraded by JMP Securities | IO - GuruFocus
Iovance Biotherapeutics (IOVA) Stock Rating Maintained, Price Ta - GuruFocus
JMP Securities Downgrades Iovance Biotherapeutics (LSE:0JDK) - Nasdaq
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Securities Fraud Investigation Into Iovance Biotherapeutics, Inc. (IOVA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Iovance Biotherapeutics (IOVA) Shares Plummet on Revenue Miss an - GuruFocus
Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi - Endpoints News
Iovance Biotherapeutics (IOVA) Shares Plummet on Revenue Miss and Forecast Cut - GuruFocus
Iovance falls after guidance cut, revenue miss - MSN
Iovance stock falls after guidance cut, Q1 miss (IOVA:NASDAQ) - Seeking Alpha
Why Iovance Biotherapeutics Stock Is Crashing Today - AOL.com
Iovance Biotherapeutics (IOVA) Downgraded by JMP Securities | IOVA Stock News - GuruFocus
Iovance Stock Sinks 46%. Here’s Why the Biotech Is Tumbling. - Barron's
Why Iovance (IOVA) Stock Is Plummeting Today - GuruFocus
Iovance Biotherapeutics (IOVA) Price Target Cut by TD Cowen | IOVA Stock News - GuruFocus
Expert Outlook: Iovance Biotherapeutics Through The Eyes Of 9 Analysts - Benzinga
Iovance Biotherapeutics (IOVA) Downgraded Amid Concerns Over Lau - GuruFocus
No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed (NASDAQ:IOVA) - Seeking Alpha
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% On '25 View Cut - Barchart.com
Sector Update: Health Care - marketscreener.com
Baird Downgrades Iovance Biotherapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $20 - marketscreener.com
Iovance Biotherapeutics (IOVA) Price Target Cut Following Revised Revenue Outlook | IOVA Stock News - GuruFocus
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut - Zacks Investment Research
Iovance Biotherapeutics (IOVA) Price Target Lowered by HC Wainwright | IOVA Stock News - GuruFocus
Iovance Biotherapeutics (IOVA) Target Price Reduced but Buy Rating Maintained | IOVA Stock News - GuruFocus
Iovance Biotherapeutics: Q1 Earnings Snapshot - New Haven Register
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 - GlobeNewswire
Iovance Biotherapeutics Q1 Loss Narrows, Revenue Rises - marketscreener.com
Iovance Biotherapeutics Reports Q1 2025 Financial Results - TipRanks
Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ... - Yahoo Finance
Decoding Iovance Biotherapeutics Inc (IOVA): A Strategic SWOT Insight - GuruFocus
(IOVA) Technical Data - news.stocktradersdaily.com
Iovance Biotherapeutics (IOVA) Projects Revenue Growth and Expanded Market Reach - GuruFocus
Iovance Biotherapeutics: Buy Rating Amid Signs of Recovery and Growth Potential - TipRanks
Iovance revises 2025 revenue guidance to $250M-$300M amid ATC expansion - MSN
Iovance Biotherapeutics earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Iovance Biotherapeutics misses Q1 2025 EPS forecasts, stock drops - Investing.com
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
IOVANCE BIOTHERAPEUTICS, INC. SEC 10-Q Report - TradingView
Iovance Biotherapeutics (IOVA) Q1 2025 Earnings Miss Estimates - GuruFocus
Iovance (IOVA) Misses Q1 Revenue Expectations, Projects Growth in Q2 | IOVA Stock News - GuruFocus
Iovance Biotherapeutics Inc Reports Q1 2025 Earnings: EPS Misses at -$0.36, Revenue Falls Short at $49.3 Million - GuruFocus
Iovance Biotherapeutics (IOVA) Sees Increased Options Activity A - GuruFocus
Earnings Flash (IOVA) Iovance Biotherapeutics Reports Q1 Revenue $49.3M, vs. FactSet Est of $82.4M - marketscreener.com
Uncovering Potential: Iovance Biotherapeutics's Earnings Preview - Nasdaq
Iovance Biotherapeutics (NasdaqGM:IOVA) Sees 3% Price Increase Over Last Month - Yahoo Finance
Iovance Biotherapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Iovance Biotherapeutics’ SWOT analysis: promising immunotherapy stock faces challenges - Investing.com
My 3 Favorite Stocks to Buy Right Now - The Motley Fool
With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space - insights.citeline.com
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):